Rituximab plus chemotherapy, CD34+cell selection and high-dose chemotherapy in advanced stage mantle-cell lymphoma.

被引：0
|
作者：
Martinelli, G [1 ]
Alietti, A [1 ]
Cinieri, S [1 ]
Rabascio, C [1 ]
Corsini, C [1 ]
Agazzi, A [1 ]
De Luzio, K [1 ]
Cocorcchio, E [1 ]
Ferrucci, PF [1 ]
Laszlo, D [1 ]
Bertolini, F [1 ]
机构：
[1] European Inst Oncol, Div Hematoncol, Milan, Italy
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2550
引用
收藏
页码：648A / 648A
页数：1
相关论文
共 50 条
  • [21] Cladribine plus rituximab for the initial treatment of mantle cell lymphoma.
    Pindyck, T.
    Spurgeon, S. E.
    Okada, C. Y.
    Epner, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Intensive chemotherapy and autologous stem cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle cell lymphoma: A matched pair analysis.
    Mangel, J
    Leitch, HA
    Connors, JM
    Buckstein, R
    Imrie, K
    Spaner, D
    Berinstein, NL
    BLOOD, 2002, 100 (11) : 780A - 780A
  • [23] Rituximab plus chemotherapy in follicular and mantle cell lymphomas
    Hiddemann, W
    Dreyling, M
    Unterhalt, M
    SEMINARS IN ONCOLOGY, 2003, 30 (01) : 16 - 20
  • [24] High-Dose Chemotherapy plus Stem Cell Transplantation in Advanced Germ Cell Cancer: A Review
    Connolly, Roisin M.
    McCaffrey, John A.
    EUROPEAN UROLOGY, 2009, 56 (01) : 57 - 64
  • [25] High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
    Romaguera, JE
    Fayad, L
    Rodriguez, MA
    Broglio, KR
    Hagemeister, FB
    Pro, B
    McLaughlin, P
    Younes, A
    Samaniego, F
    Goy, A
    Sarris, AH
    Dang, NH
    Wang, M
    Beasley, V
    Medeiros, LJ
    Katz, RL
    Gagneja, H
    Samuels, BI
    Smith, TL
    Cabanillas, FF
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 7013 - 7023
  • [26] Impact of mantle cell lymphoma contamination of autologous stem cell grafts on outcome after high-dose chemotherapy
    Roerden, M.
    Wirths, S.
    Soekler, M.
    Bethge, W. A.
    Lengerke, C.
    Vogel, W.
    Walz, J. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 152 - 153
  • [27] Efficiency of rituximab plus DRAP in the treatment of patients with mantle cell lymphoma.
    Jaccard, A
    Touati, M
    Gachard, N
    Chaury, MP
    Remenieras, L
    Turlure, P
    Bordessoule, D
    BLOOD, 2002, 100 (11) : 315B - 315B
  • [28] Dexa-BEAM:: An effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma
    Josting, A
    Reiser, M
    Wickramanayake, PD
    Rueffer, U
    Draube, A
    Söhngen, D
    Tesch, H
    Wolf, J
    Diehl, V
    Engert, A
    LEUKEMIA & LYMPHOMA, 2000, 37 (1-2) : 185 - 187
  • [29] Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome after High-Dose Chemotherapy
    Roerden, Malte
    Wirths, Stefan
    Soekler, Martin
    Bethge, Wolfgang A.
    Vogel, Wichard
    Walz, Juliane S.
    CANCERS, 2021, 13 (11)
  • [30] The unfavourable clinical outcome of mantle cell lymphoma is not improved by high-dose chemotherapy and autologous stem cell transplantation
    Van de Velde, AL
    Gadisseur, AP
    Steel, E
    Van Steenweghen, S
    Schroyens, W
    Berneman, ZN
    Zachee, P
    BONE MARROW TRANSPLANTATION, 2004, 33 : S350 - S350
12345